{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(1)"],"submitter":["Horcajada JP"],"funding":["Ferrer Internacional, S.A."],"pubmed_abstract":["<h4>Purpose</h4>To design a randomized clinical trial to assess the efficacy and safety of favipiravir in patients with COVID-19 disease with pneumonia.<h4>Methods</h4>A randomized, double blind, placebo-controlled clinical trial of favipiravir in patients with COVID-19 pneumonia was conducted in three Spanish sites. Randomization 1:1 to favipiravir or placebo (in both groups added to the Standard of Care) was performed to treat the patients with COVID-19 pneumonia. The primary endpoint was \"time to clinical improvement,\" measured as an improvement for ≥ two categories on a 7-point WHO ordinal scale in an up to 28 days' time frame.<h4>Results</h4>Forty-four patients were randomized (23 in the favipiravir group and 21 in the placebo group). The median time to clinical improvement was not di"],"journal":["Pneumonia (Nathan Qld.)"],"pagination":["3"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10894471"],"repository":["biostudies-literature"],"pubmed_title":["Safety and efficacy of favipiravir in COVID-19 patients with pneumonia. A randomized, double-blind, placebo-controlled study (FAVID)."],"pmcid":["PMC10894471"],"pubmed_authors":["Real M","Knobel H","COVID-HJ23 group","Pelegrin I","COVID-MAR Research group","Gomez-Junyent J","Febrer AM","Castaneda-Espinosa S","Montero MM","Aldonza R","Brianso S","Sorli L","Barrientos A","Gomez-Zorrilla S","Lopez-Montesinos I","Guerri-Fernandez R","Arrieta-Aldea I","Alibalic A","Tarrago C","Sanchez-Martinez F","Camaron J","Horcajada JP","Fernandez A","Bertran L","Canas-Ruano E","Villar-Garcia J","Auguet-Quintilla T","Duran-Taberna M","Sendra E","Arenas-Miras M"],"additional_accession":[]},"is_claimable":false,"name":"Safety and efficacy of favipiravir in COVID-19 patients with pneumonia. A randomized, double-blind, placebo-controlled study (FAVID).","description":"<h4>Purpose</h4>To design a randomized clinical trial to assess the efficacy and safety of favipiravir in patients with COVID-19 disease with pneumonia.<h4>Methods</h4>A randomized, double blind, placebo-controlled clinical trial of favipiravir in patients with COVID-19 pneumonia was conducted in three Spanish sites. Randomization 1:1 to favipiravir or placebo (in both groups added to the Standard of Care) was performed to treat the patients with COVID-19 pneumonia. The primary endpoint was \"time to clinical improvement,\" measured as an improvement for ≥ two categories on a 7-point WHO ordinal scale in an up to 28 days' time frame.<h4>Results</h4>Forty-four patients were randomized (23 in the favipiravir group and 21 in the placebo group). The median time to clinical improvement was not di","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2025-05-18T12:52:32.415Z","creation":"2025-04-19T21:04:41.016Z"},"accession":"S-EPMC10894471","cross_references":{"pubmed":["38402214"],"doi":["10.1186/s41479-023-00124-6"]}}